Breaking News Instant updates and real-time market news.

PEP

PepsiCo

$110.19

-1.24 (-1.11%)

, WDC

Western Digital

$86.40

-0.31 (-0.36%)

10:27
10/02/17
10/02
10:27
10/02/17
10:27

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PepsiCo (PEP) downgraded to Hold from Buy at Jefferies with analyst Kevin Grundy saying North American beverage trends continue to deteriorate and Pepsi's likely need for reinvestment should "cap the stock" over the next 12 months. 2. Western Digital (WDC) downgraded to Neutral from Outperform at Baird with analyst Tristan Gerra saying he believes the potential outcomes from the company's ongoing litigation with Toshiba (TOSYY) "range from neutral to significantly negative" and the ongoing fight will cap the stock's valuation in the near-term. 3. Uniti Group (UNIT) downgraded to Neutral from Overweight at JPMorgan with analyst Philip Cusick saying the "theme of Windstream's (WIN) distress continues to increase in volume." 4. Parker-Hannifin (PH) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Nigel Coe saying he sees a more balanced risk-reward following the stock's strong outperformance since the election. 5. bluebird bio (BLUE) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Matthew Harrison saying he believes the risks ahead of the company's presentation of LentiGlobin sickle cell data at December's American Society of Hematology meeting remains underappreciated. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

PEP

PepsiCo

$110.19

-1.24 (-1.11%)

WDC

Western Digital

$86.40

-0.31 (-0.36%)

UNIT

Uniti Group

PH

Parker-Hannifin

$175.15

0.13 (0.07%)

BLUE

bluebird bio

$137.35

-3.8 (-2.69%)

  • 02

    Oct

  • 04

    Oct

  • 04

    Oct

  • 02

    Nov

PEP PepsiCo
$110.19

-1.24 (-1.11%)

09/14/17
MACQ
09/14/17
INITIATION
Target $125
MACQ
Outperform
PepsiCo initiated with an Outperform at Macquarie
Macquarie analyst Caroline Levy initiated PepsiCo with an Outperform and a $125 price target saying management has continued to evolve the company to win as consumer changes accelerate. Levy said Pepsi has leading brands in big markets, a best in class snack business, and financial discipline.
10/02/17
JEFF
10/02/17
DOWNGRADE
Target $108
JEFF
Hold
PepsiCo downgraded to Hold from Buy at Jefferies
Jefferies analyst Kevin Grundy downgraded PepsiCo to Hold and cut his price target for the shares to $108 from $133. The food and beverage company closed Friday down 21c to $111.43. North American beverage trends continue to deteriorate and Pepsi's likely need for reinvestment should "cap the stock" over the next 12 months, Grundy tells investors in a research note. The analyst adds that food valuation multiples are contracting and that Pepsi has high exposure to a difficult U.S. environment.
09/08/17
09/08/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PepsiCo (PEP) downgraded to Neutral on declining US beverage sales at Credit Suisse with analyst Laurent Grandet saying risk/reward is "balanced" following an 11% share appreciation over the past year, especially with US beverage sales struggling year-to-date. 2. Chipotle (CMG) downgraded to Underperform from Market Perform at Cowen with analyst Andrew Charles citing proprietary survey data that indicates the company's quality and value perceptions remain at trough levels, leading him to believe the sales recovery will continue to trail investor expectations. 3. Aflac (AFL) downgraded to Underperform from Neutral at BofA/Merrill with analyst Seth Weiss citing relative valuation. 4. Kroger (KR) downgraded to Perform from Outperform at Oppenheimer with analyst Rupesh Parikh citing the company's second quarter results. 5. Rice Energy (RICE) downgraded to Neutral from Buy at Goldman Sachs with analyst Brian Singer citing valuation following recent outperformance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/02/17
SUSQ
10/02/17
NO CHANGE
Target $135
SUSQ
Positive
PepsiCo could be next takeout for AB In Bev, says Susquehanna
Susquehanna analyst Pablo Zuanic noted Pepsico (PEP) reports Q3 on October 3rd and he projects year-to-date metrics and earnings are below consensus. He trimmed his North American sales growth on weaker trends than expected, but he believes the potential miss could already be reflected in the shares. The analyst said based on valuation and fundamentals the stock deserves a Neutral rating but he continues to see it as the next logical target for AB InBev (BUD) in a joint bid with Kraft Heinz (KHC). Zuanic keeps a $135 price target on PepsiCo shares.
WDC Western Digital
$86.40

-0.31 (-0.36%)

09/25/17
MSCO
09/25/17
NO CHANGE
Target $123
MSCO
Overweight
Western Digital shares overreacted to JV news from Toshiba, says Morgan Stanley
After Toshiba (TOSYY) selected a Bain-led consortium as the preferred buyer of its Toshiba Memory Corporation business, Morgan Stanley analyst Katy Huberty said the reaction in Western Digital (WDC) shares to the news was an overreaction. She notes that the deal is an investment only, not a transfer of IP or manufacturing knowledge, and Western Digital has already filed additional arbitration proceedings. The analyst, who thinks both Toshiba and Western are best served by working closely to continue the joint venture, keeps an Overweight rating and $123 price target on WD shares.
09/21/17
LOOP
09/21/17
NO CHANGE
LOOP
Western Digital could still obtain stake in Toshiba unit, says Loop Capital
After Toshiba (TOSBF) agreed to sell its memory unit to a consortium that does not include Western Digital (WDC), Loop Capital analyst Ananda Baruah says that Western Digital could force Toshiba to include it in the consortium going forward by delaying the deal's implementation. The analyst notes that Western Digital said that its access to NAND supply is "secure." She thinks the company can continue to benefit from strong NAND/SSD pricing and keeps a $140 price target and a Buy rating on the shares.
09/20/17
COWN
09/20/17
NO CHANGE
COWN
Western Digital risk/reward still attractive, says Cowen
After it was reported that Toshiba (TOSBF) could sell its NAND business to a Bain-led consortium, Cowen analyst Karl Ackerman says that in a "base case, status quo" scenario, in which Western Digital (WDC) retains "ownership in Flash Ventures and access to NAND IP and manufacturing," the stock's value is $117 per share. Meanwhile, "in an uber bear case," which includes Toshiba successfully selling its memory business to a third party, Western Digital's stock would be worth $60 per share, the analyst stated. Finally, if Western Digital acquire more than 20% of the memory business, adding up to $1.50 to its annual EPS, the stock could "approach" roughly $135, according to the analyst. Given these scenarios and Ackerman's belief that Western Digital's current stock price implies that its NAND business is worth $45 per share of 50% of what it paid for the business, he thinks that the stock's risk/reward ratio is attractive. He keeps a $117 price target and an Outperform rating on the shares.
10/02/17
BARD
10/02/17
DOWNGRADE
Target $93
BARD
Neutral
Western Digital downgraded to Neutral from Outperform at Baird
Baird analyst Tristan Gerra downgraded Western Digital (WDC) to Neutral from Outperform, saying he believes the potential outcomes from the company's ongoing litigation with Toshiba (TOSYY) "range from neutral to significantly negative" and the ongoing fight will cap the stock's valuation in the near-term. Meanwhile, NAND flash pricing is peaking and by the time the litigation is resolved investors will likely focus on a less favorable NAND pricing environment, he tells investors. Gerra cut his price target on Western Digital shares to $93 from $120.
UNIT Uniti Group

09/19/17
RAJA
09/19/17
NO CHANGE
RAJA
Windstream, Uniti selloff on S&P change unfounded, says Raymond James
Raymond James analyst Frank Louthan attributes the weakness today in shares of Windstream (WIN) and Uniti Group (UNIT) to Standard & Poor's lowering its ratings on both companies to B from B+. The rating agency's analysis is "very weak" and seems a reaction to recent market moves rather than new information, Louthan tells investors in an intraday research note. The review does not take into account the recent "highly" free cash flow accretive acquisitions or the dividend cut, the analyst adds. He calls the selloff in the stocks "unfounded."
09/26/17
SBSH
09/26/17
DOWNGRADE
Target $18
SBSH
Neutral
Uniti Group downgraded to Neutral wiht $18 price target at Citi
Citi analyst Michael Rollins downgraded Uniti Group (UNIT) to Neutral from Buy and cut his price target for the shares to $18 from $27. The widening of Windstream's (WIN) bond spreads could drive further near-term underperformance for Uniti given their relatively high correlation to Uniti's dividend yield, Rollins tells investors in a research note. He believes potential catalysts for Uniti may be further out than previously thought.
10/02/17
JPMS
10/02/17
DOWNGRADE
Target $16
JPMS
Neutral
Uniti Group downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Philip Cusick downgraded Uniti Group (UNIT) to Neutral saying the "theme of Windstream's (WIN) distress continues to increase in volume."Shares of Uniti could weaken further before its relationship with Windstrean is confirmed, Cusick tells investors in a research note. He believes Windstrean's fight with creditors could impact its ability to pay Uniti's lease. The analyst cut his price target for Uniti Group shares to $16 from $27.
09/26/17
SBSH
09/26/17
DOWNGRADE
SBSH
Neutral
Uniti Group downgraded to Neutral from Buy at Citi
PH Parker-Hannifin
$175.15

0.13 (0.07%)

10/02/17
MSCO
10/02/17
DOWNGRADE
MSCO
Equal Weight
Parker-Hannifin downgraded to Equal Weight from Overweight at Morgan Stanley
10/02/17
10/02/17
DOWNGRADE
Target $188

Equal Weight
Parker-Hannifin downgraded after post-election outperformance at Morgan Stanley
As previously reported, Morgan Stanley analyst Nigel Coe downgraded Parker-Hannifin (PH) to Equal Weight from Overweight, as he sees a more balanced risk-reward following the stock's strong outperformance since the election. Coe no longer sees room for Parker-Hannifin to expand its relative premium versus the broader Electrical Equipment and Multi-Industry sector at this point in the cycle, he tells investors. Coe raised his price target on Parker shares to $188 from $187. The analyst also upgraded Stanley Black & Decker (SWK) to Overweight from Equal Weight this morning.
07/11/17
WOLF
07/11/17
INITIATION
Target $182
WOLF
Outperform
Parker-Hannifin initiated with an Outperform at Wolfe Research
Wolfe Research initiated Parker-Hannifin with an Outperform and a $182 price target.
08/04/17
STFL
08/04/17
NO CHANGE
STFL
Parker-Hannifin guidance 'looks conservative,' says Stifel
Stifel analyst Nathan Jones says that Parker-Hannifin's guidance for 2.5% growth in 2H18 " looks conservative given global macro trends and recent order rates." He raised his price target on the shares to $198 from $189 and keeps a Buy rating on the stock.
BLUE bluebird bio
$137.35

-3.8 (-2.69%)

10/02/17
MSCO
10/02/17
DOWNGRADE
MSCO
Underweight
bluebird bio downgraded to Underweight from Equal Weight at Morgan Stanley
10/02/17
10/02/17
DOWNGRADE
Target $105

Underweight
bluebird bio downgraded to Underweight on sickle cell risk at Morgan Stanley
As previously reported, Morgan Stanley analyst Matthew Harrison downgraded bluebird bio (BLUE) to Underweight from Equal Weight, as he believes the risks ahead of the company's presentation of LentiGlobin sickle cell data at December's American Society of Hematology meeting remains underappreciated. The analyst, who notes the stock is up over 40% since Gilead's (GILD) acquisition of Kite Pharma (KITE) set off excitement about the CAR-T space that blue is also in, doesn't believe the ASH data will demonstrate the improvement in hemoglobin production necessary to increase confidence in sickle cell genetherapy, he tells investors. Harrison keeps a $105 price target on bluebird bio shares.
09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
bluebird bio initiated with an Overweight at Barclays
Barclays initiated bluebird bio with an Overweight and a $151 price target, citing the company's strategic focus on diseases curable with hematopoietic stem cell transplants, and "impressive" efficacy/safety data for bb2121.
08/31/17
BMOC
08/31/17
NO CHANGE
BMOC
bluebird bio price target raised to $134 from $108 at BMO Capital
BMO Capital analyst Matthew Luchini increased his price target on bluebird (BLUE) after the FDA approved Novartis' (NVS) CAR-T treatment for the treatment of pediatric ALL. The analyst thinks that the approval lowers the risk facing all CAR-T companies. He now sees a 60% chance of approval for bluebird's CAR-T treatment, bb2121, up from 45% previously, and he raised his estimate of the price of the treatment to $300,000 from $225,000 based on the $475,000 price of Novartis' treatment. He keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

MSBI

Midland States

$33.03

-0.07 (-0.21%)

19:02
10/16/17
10/16
19:02
10/16/17
19:02
Hot Stocks
Midland States to acquire Alpine Bancorporation in roughly $181M deal »

Midland States Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 15

    Nov

MYL

Mylan

$38.18

0.23 (0.61%)

, AGN

Allergan

$198.41

-7.11 (-3.46%)

18:46
10/16/17
10/16
18:46
10/16/17
18:46
Hot Stocks
Mylan CEO: 'Pleased' with court ruling on Allergan's Restasis patents »

Mylan (MYL) announced…

MYL

Mylan

$38.18

0.23 (0.61%)

AGN

Allergan

$198.41

-7.11 (-3.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 20

    Oct

  • 23

    Oct

  • 01

    Nov

  • 06

    Nov

  • 03

    Dec

NFLX

Netflix

$202.68

3.19 (1.60%)

18:44
10/16/17
10/16
18:44
10/16/17
18:44
Hot Stocks
Netflix says seeing steady growth, great success for streaming »

Says still has bias…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 22

    Oct

PCG

PG&E

$53.43

-4.29 (-7.43%)

18:42
10/16/17
10/16
18:42
10/16/17
18:42
Hot Stocks
PG&E sees restoring service to all electric customers in CA affected by fires »

PG&E said that more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

  • 05

    Nov

  • 05

    Nov

CYTR

CytRx

$0.38

-0.0142 (-3.64%)

18:29
10/16/17
10/16
18:29
10/16/17
18:29
Hot Stocks
CytRx granted listing extension pending results of stockholder vote »

CytRx 's request for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

EADSY

Airbus

$22.75

-0.07 (-0.31%)

, BDRBF

Bombardier

$1.88

0.03 (1.62%)

18:27
10/16/17
10/16
18:27
10/16/17
18:27
Hot Stocks
Airbus and Bombardier announce C Series partnership »

Airbus (EADSY) and…

EADSY

Airbus

$22.75

-0.07 (-0.31%)

BDRBF

Bombardier

$1.88

0.03 (1.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

18:16
10/16/17
10/16
18:16
10/16/17
18:16
Conference/Events
Immune Design to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 08

    Nov

PG

Procter & Gamble

$93.14

0.1 (0.11%)

18:15
10/16/17
10/16
18:15
10/16/17
18:15
Hot Stocks
Trian: P&G board election results 'too close to call' »

Trian Fund Management,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

AMZN

Amazon.com

$1,006.34

3.4 (0.34%)

18:14
10/16/17
10/16
18:14
10/16/17
18:14
Periodicals
NJ leaders offer up to $7B in tax incentives to lure Amazon to Newark, WSJ says »

New Jersey Governor Chris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 22

    Oct

  • 26

    Oct

BDRBF

Bombardier

$1.88

0.03 (1.62%)

, EADSY

Airbus

$22.75

-0.07 (-0.31%)

18:09
10/16/17
10/16
18:09
10/16/17
18:09
Periodicals
Bombardier in talks with Airbus over CSeries jet unit JV, WSJ reports »

Bombardier (BDRBF) is in…

BDRBF

Bombardier

$1.88

0.03 (1.62%)

EADSY

Airbus

$22.75

-0.07 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:55
10/16/17
10/16
17:55
10/16/17
17:55
Hot Stocks
Impax jumps 6% in after-hours after WSJ says Amneal deal near »

Shares of Impax are up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:51
10/16/17
10/16
17:51
10/16/17
17:51
Periodicals
Impax and Amneal close to merger pact, WSJ says »

Impax Laboratories and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

AGII

Argo Group

$62.90

-0.25 (-0.40%)

17:36
10/16/17
10/16
17:36
10/16/17
17:36
Hot Stocks
Argo Group provides preliminary Q3 loss estimate »

Argo Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDEF

First Defiance Financial

$53.65

-0.25 (-0.46%)

17:34
10/16/17
10/16
17:34
10/16/17
17:34
Earnings
First Defiance Financial reports Q3 EPS 92c, consensus 89c »

Reports Q3 NII $ $25.0M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

BRO

Brown & Brown

$48.97

-0.42 (-0.85%)

17:33
10/16/17
10/16
17:33
10/16/17
17:33
Earnings
Brown & Brown reports Q3 EPS 53c, consensus 50c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

ORIG

Ocean Rig UDW

$26.18

0.51 (1.99%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
Ocean Rig holder BlueMountain intends to recommend company hire advisers »

Ocean Rig UDW holder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$202.68

3.19 (1.60%)

, IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

NFLX

Netflix

$202.68

3.19 (1.60%)

IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

SAVE

Spirit Airlines

$33.47

-0.33 (-0.98%)

UNH

UnitedHealth

$193.20

0.68 (0.35%)

BMI

Badger Meter

$50.80

-0.6 (-1.17%)

SONC

Sonic

$24.80

0.42 (1.72%)

ABEO

Abeona Therapeutics

$16.70

0.6 (3.73%)

VICL

Vical

$2.86

0.04 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

  • 23

    Oct

  • 08

    Nov

  • 17

    Oct

FDC

First Data

$18.01

0.39 (2.21%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Hot Stocks
First Data CAO sells 3,996 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

ROSG

Rosetta Genomics

$1.00

-0.0479 (-4.57%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Syndicate
Breaking Syndicate news story on Rosetta Genomics »

Rosetta Genomics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRS

Harris

$135.90

-0.66 (-0.48%)

17:27
10/16/17
10/16
17:27
10/16/17
17:27
Hot Stocks
Harris awarded $100M government contract modification »

Harris Corp., Clifton,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$259.75

-0.99 (-0.38%)

17:26
10/16/17
10/16
17:26
10/16/17
17:26
Hot Stocks
Boeing awarded $240.2M government contract »

The Boeing Co., Oklahoma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

PI

Impinj

$34.98

-0.71 (-1.99%)

17:22
10/16/17
10/16
17:22
10/16/17
17:22
Hot Stocks
Impinj COO sells 7,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 14

    Nov

  • 15

    Nov

ADOM

Adomani

$6.50

-0.36 (-5.25%)

17:21
10/16/17
10/16
17:21
10/16/17
17:21
Syndicate
Breaking Syndicate news story on Adomani »

Adomani files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAVE

Spirit Airlines

$33.47

-0.33 (-0.98%)

17:20
10/16/17
10/16
17:20
10/16/17
17:20
Hot Stocks
Spirit Airlines raises Q3 total RASM view to (6.5%) from (8.5%)-(7%) »

Sees Q3 ASMs up 18%. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RESN

Resonant

$4.38

-0.08 (-1.79%)

17:16
10/16/17
10/16
17:16
10/16/17
17:16
Hot Stocks
Breaking Hot Stocks news story on Resonant »

Longboard raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.